Vidarbha News

Acute Respiratory Distress Syndrome Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook

 Breaking News
  • No posts were found

Acute Respiratory Distress Syndrome Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook

September 07
01:02 2023
Acute Respiratory Distress Syndrome Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Acute Respiratory Distress Syndrome pipeline constitutes 60+ key companies continuously working towards developing 60+ Acute Respiratory Distress Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Acute Respiratory Distress Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Acute Respiratory Distress Syndrome Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Respiratory Distress Syndrome Market.

 

Some of the key takeaways from the Acute Respiratory Distress Syndrome Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Acute Respiratory Distress Syndrome treatment therapies with a considerable amount of success over the years. 
  • Acute Respiratory Distress Syndrome companies working in the treatment market are Meridigen Biotech, AVM Biotechnology, Aqualung Therapeutics, Cynata Therapeutics, Histocell, BioMarck Pharmaceuticals, Exvastat, Vasomune Therapeutics, Athersys, and others, are developing therapies for the Acute Respiratory Distress Syndrome treatment 
  • Emerging Acute Respiratory Distress Syndrome therapies in the different phases of clinical trials are- UMC 119 06, AVM0703, ALT-100, CYP 001, HCR040, BIO-11006, Imatinib, AV 001 , MultiStem cell therapy, and others are expected to have a significant impact on the Acute Respiratory Distress Syndrome market in the coming years.  
  • In February 2021, In a statement, Athersys stated that it had collaborated with HEALIOS. The goal of the cooperation agreement is to reaffirm the parties’ shared dedication to the cooperative growth of MultiStem in Japan.
  • In March 2021, SIRS Therapeutics and F4 Pharma have signed a licencing and collaboration agreement with Partner Therapeutics to help with the development of FX-06. There are numerous potential uses for this synthetic peptide.
  • In June 2020, The US FDA granted NeuroRx Fast Track designation for the exploration of RLF-100 (Aviptadil) for the treatment of acute lung injury/acute respiratory distress syndrome linked to COVID-19, according to an announcement made by NeuroRx in collaboration with Relief Therapeutics.
  • In December 2020, Remestemcel-L has been given Fast Track designation by the Food and Drug Administration (FDA) for the treatment of acute respiratory distress syndrome (ARDS) brought on by coronavirus illness 2019 (COVID-19).
  • In November 2020, Remestemcel-L will be developed, manufactured, and sold by Novartis under an exclusive worldwide licence and partnership agreement with Mesoblast to treat acute respiratory distress syndrome.
  • In September 2020, According to Athersys, the acute respiratory distress syndrome (ARDS) programme has been given the US FDA’s Regenerative Medicine AdvancedTherapy (RMAT) designation for MultiStem cell therapy. MultiStem cell treatment for ARDS received Fast Track designation from the US FDA in May 2019.

 

Acute Respiratory Distress Syndrome Overview

The chronic lung disease known as asthma causes the airways to become inflamed and hyperactive. Asthma has a wide range of signs and symptoms that can be brought on by breathing in environmental allergens including pollen, dust, animal dander, mould, or other irritants.

 

Get a Free Sample PDF Report to know more about Acute Respiratory Distress Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-pipeline-insight

 

Emerging Acute Respiratory Distress Syndrome Drugs Under Different Phases of Clinical Development Include:

  • UMC 119 06: Meridigen Biotech
  • AVM0703: AVM Biotechnology
  • ALT-100: Aqualung Therapeutics
  • CYP 001: Cynata Therapeutics
  • HCR040: Histocell
  • BIO-11006: BioMarck Pharmaceuticals
  • Imatinib: Exvastat
  • AV 001: Vasomune Therapeutics
  • MultiStem cell therapy: Athersys

 

Acute Respiratory Distress Syndrome Route of Administration

Acute Respiratory Distress Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

 

Acute Respiratory Distress Syndrome Molecule Type

Acute Respiratory Distress Syndrome Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment

  • Acute Respiratory Distress Syndrome Assessment by Product Type
  • Acute Respiratory Distress Syndrome By Stage and Product Type
  • Acute Respiratory Distress Syndrome Assessment by Route of Administration
  • Acute Respiratory Distress Syndrome By Stage and Route of Administration
  • Acute Respiratory Distress Syndrome Assessment by Molecule Type
  • Acute Respiratory Distress Syndrome by Stage and Molecule Type

 

DelveInsight’s Acute Respiratory Distress Syndrome Report covers around 60+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Acute Respiratory Distress Syndrome product details are provided in the report. Download the Acute Respiratory Distress Syndrome pipeline report to learn more about the emerging Acute Respiratory Distress Syndrome therapies

 

Some of the key companies in the Acute Respiratory Distress Syndrome Therapeutics Market include:

Key companies developing therapies for Acute Respiratory Distress Syndrome are – Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others.

 

Acute Respiratory Distress Syndrome Pipeline Analysis:

The Acute Respiratory Distress Syndrome pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Acute Respiratory Distress Syndrome with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Respiratory Distress Syndrome Treatment.
  • Acute Respiratory Distress Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Acute Respiratory Distress Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Respiratory Distress Syndrome market.
  • The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Acute Respiratory Distress Syndrome drugs and therapies

 

Acute Respiratory Distress Syndrome Pipeline Market Drivers

  • Increasing R&D activities, increasing incidence of ARDS, Non-competitive Landscape are some of the important factors that are fueling the Acute Respiratory Distress Syndrome Market.

 

Acute Respiratory Distress Syndrome Pipeline Market Barriers

  • However, lack of awareness about the disease, mechanical ventilation for management, missed-diagnoses of ARDS and other factors are creating obstacles in the Acute Respiratory Distress Syndrome Market growth.

 

Scope of Acute Respiratory Distress Syndrome Pipeline Drug Insight    

  • Coverage: Global
  • Key Acute Respiratory Distress Syndrome Companies: Meridigen Biotech, AVM Biotechnology, Aqualung Therapeutics, Cynata Therapeutics, Histocell, BioMarck Pharmaceuticals, Exvastat, Vasomune Therapeutics, Athersys, and others
  • Key Acute Respiratory Distress Syndrome Therapies: UMC 119 06, AVM0703, ALT-100, CYP 001, HCR040, BIO-11006, Imatinib, AV 001 , MultiStem cell therapy, and others
  • Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies
  • Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers 

 

Request for Sample PDF Report for Acute Respiratory Distress Syndrome Pipeline Assessment and clinical trials

 

Table of Contents 

1. Acute Respiratory Distress Syndrome Report Introduction

2. Acute Respiratory Distress Syndrome Executive Summary

3. Acute Respiratory Distress Syndrome Overview

4. Acute Respiratory Distress Syndrome- Analytical Perspective In-depth Commercial Assessment

5. Acute Respiratory Distress Syndrome Pipeline Therapeutics

6. Acute Respiratory Distress Syndrome Late Stage Products (Phase II/III)

7. Acute Respiratory Distress Syndrome Mid Stage Products (Phase II)

8. Acute Respiratory Distress Syndrome Early Stage Products (Phase I)

9. Acute Respiratory Distress Syndrome Preclinical Stage Products

10. Acute Respiratory Distress Syndrome Therapeutics Assessment

11. Acute Respiratory Distress Syndrome Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Acute Respiratory Distress Syndrome Key Companies

14. Acute Respiratory Distress Syndrome Key Products

15. Acute Respiratory Distress Syndrome Unmet Needs

16 . Acute Respiratory Distress Syndrome Market Drivers and Barriers

17. Acute Respiratory Distress Syndrome Future Perspectives and Conclusion

18. Acute Respiratory Distress Syndrome Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Categories